Acrivon Therapeutics (ACRV) Amortizatization of Intangibles (2022 - 2026)
Acrivon Therapeutics (ACRV) posted quarterly Amortizatization of Intangibles of -$161000.0 for Q1 2026, down 144.72% year-over-year from $360000.0 in Q1 2025, and down 23.85% quarter-over-quarter from -$130000.0 in Q4 2025.
Acrivon Therapeutics (ACRV) Amortizatization of Intangibles (2022 - 2026) Analysis & Trends
Acrivon Therapeutics (ACRV) has reported Amortizatization of Intangibles for 5 consecutive years, with -$161000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Amortizatization of Intangibles fell 144.72% year-over-year to -$161000.0; the TTM figure through Mar 2026 stood at -$84000.0 (down 102.36% YoY), while the FY2025 annual figure was $437000.0, down 88.43% from the prior year.
- Amortizatization of Intangibles slipped to -$161000.0 in Q1 2026 per ACRV's latest filing, from -$130000.0 in the prior quarter.
- Across five years, Amortizatization of Intangibles topped out at $1.2 million in Q3 2024 and bottomed at -$161000.0 in Q1 2026.
- Historically, Amortizatization of Intangibles has averaged $563714.3 across 5 years, with a median of $628500.0 in 2023.
- Annual changes were most pronounced in 2024 — Amortizatization of Intangibles jumped 62.26% — and 2026, when it tumbled 144.72%.
- Acrivon Therapeutics' Amortizatization of Intangibles stood at $516000.0 in 2022, then soared by 31.78% to $680000.0 in 2023, then soared by 31.91% to $897000.0 in 2024, then sank by 114.49% to -$130000.0 in 2025, then slipped by 23.85% to -$161000.0 in 2026.
- Business Quant data shows ACRV's Amortizatization of Intangibles at -$161000.0 in Q1 2026, -$130000.0 in Q4 2025, and $34000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Amortizatization of Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 678,000.00 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Acrivon Therapeutics | 92.89 Mn | 92.89 Mn | - | -61,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -61,000.00 |
| Jun 30, 2026 | -61,000.00 |
| Mar 31, 2026 | -161,000.00 |
| Mar 31, 2026 | -161,000.00 |
| Dec 31, 2025 | -130,000.00 |
| Dec 31, 2025 | -130,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Sep 30, 2025 | 34,000.00 |
| Jun 30, 2025 | 173,000.00 |
| Jun 30, 2025 | 173,000.00 |
| Mar 31, 2025 | 360,000.00 |
| Mar 31, 2025 | 360,000.00 |
| Dec 31, 2024 | 897,000.00 |
| Dec 31, 2024 | 897,000.00 |
| Sep 30, 2024 | 1.20 Mn |
| Sep 30, 2024 | 1.20 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Jun 30, 2024 | 1.10 Mn |
| Mar 31, 2024 | 577,000.00 |
| Mar 31, 2024 | 577,000.00 |